Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.71 |
| ▸ | ITGAV | P06756 | 20/20 | 0.71 |
| ▸ | ITGB6 | P18564 | 12/20 | 0.70 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.70 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.70 |
| ▸ | ITGB5 | P18084 | 7/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2841513 | 0.85 | ITGB3 (0.73) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL5857835 | 0.85 | ITGB3 (0.75) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL2841233 | 0.85 | ITGB3 (0.79) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL2841311 | 0.85 | ITGB3 (0.79) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL2842687 | 0.84 | ITGB3 (0.78) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL6421707 | 0.83 | ITGAV (1.00) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL6424064 | 0.83 | ITGAV (1.00) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL6422137 | 0.83 | ITGAV (1.00) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL2841322 | 0.83 | ITGB3 (0.75) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL8335217 | 0.83 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGA2BITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | ITGB3 1/4885ITGAV 16/4885ITGB6 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.